Risk modifiers of immune-related adverse events in patients with NSCLC undergoing immunotherapy: a retrospective cohort study
Takashi Watanabe, Naoto Suzuki, Masahito Yamauchi, Naoki Iinuma, Makoto Shiozawa, Yotaro Arima, Takanobu Sasaki, Hideki Shimodaira, Syu-ichi Kanno, Kouji Okada · 2026
Read Risk modifiers of immune-related adverse events in patients with NSCLC undergoing immunotherapy: a retrospective cohort study by Takashi Watanabe, Naoto Suzuki, Masahito Yamauchi, Naoki Iinuma, Makoto Shiozawa, Yotaro Arima, Takanobu Sasaki, Hideki Shimodaira, Syu-ichi Kanno, Kouji Okada (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13576305.txt.
Description
Takashi Watanabe leads a 2026 study of immune side effects from checkpoint inhibitor therapy in lung cancer. These drugs free the immune system to attack non-small cell lung cancer, yet they can also trigger inflammation in healthy organs. The team reviewed five years of cases at a Japanese university hospital to find what shapes that risk.
Among 203 patients, 92 had at least one immune side effect, with lung inflammation the most common, followed by thyroid problems. One factor stood out in reverse: patients with heart failure developed side effects far less often, with a risk near one third of others. The link held under a second method that accounts for competing risks. A related model swapping in use of certain heart drugs also showed a link. The authors suggest heart history belongs in monitoring plans.
Catalog record
| CREATOR | Takashi Watanabe, Naoto Suzuki, Masahito Yamauchi, Naoki Iinuma, Makoto Shiozawa, Yotaro Arima, Takanobu Sasaki, Hideki Shimodaira, Syu-ichi Kanno, Kouji Okada |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42297 |
| LICENSE | https://creativecommons.org/publicdomain/zero/1.0 |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |